RxDoctor Payments Data

Jhanelle Watson

Nurse Practitioner · Hampton, VANPI 1063260875

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 95.4% of the total across 211 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 23 manufacturers reported payments, led by AstraZeneca at 24.8% of the total. Among nurse practitioner clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$6,345in general payments, 2019–2025

Across 211 payments — averaging $30.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$2K
  • ANI Pharmaceuticals, Inc.$864
  • GSK$804
  • Sanofi$597
  • Regeneron Healthcare Solutions, Inc.$545
  • Merck$311
  • plus $2K from 17 others

What the payments were for

  • Food & beverage$6,05195%
  • Education$2945%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$6,345 in reported general payments places this provider in the 95th percentile of 2,166 nurse practitioner providers in Virginia.

See all nurse practitioner providers in Virginia

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter65$71,806
Spiriva RespimatTiotropium Bromide37$33,328
Breztri AerosphereBudesonide/Glycopyr/Formoterol29$31,988
Albuterol Sulfate HfaAlbuterol Sulfate102$2,371
Ipratropium Bromide27$1,059
Ventolin HfaAlbuterol Sulfate12$746
Montelukast Sodium46$414
Methylprednisolone19$135
Fluticasone Propionate13$124
Azithromycin14$108

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$804$71,80665 claims
Boehringer IngelheimSpiriva Respimat$151$33,32837 claims
AstraZenecaBreztri Aerosphere$1,572$31,98829 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,166 nurse practitioner providers in Virginia.

Other nurse practitioner in Hampton

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →